Prøve GULL - Gratis
Pharma Stocks Slide Over Trump's Relief Fund Freeze
Mint New Delhi
|January 28, 2025
Shares of Laurus Labs on Monday fell nearly 15% as the company's ARV sales make up about 46% of its total revenue
Stocks of Indian pharma companies supplying antiretroviral (ARV) medicines used to treat HIV to African countries tumbled on Monday after a US government order halted all foreign aid funding, including its AIDS relief program.
On January 25, the US State Department put into action an executive order from President Donald Trump halting all US foreign assistance, barring Israel and Egypt, for at least 90 days to review all the programs. This includes the President's Emergency Plan for AIDS Relief (PEPFAR), which provides ARVs to people in about 50 countries, of which half are in Africa. HIV spending made up 44% of total US global health funding in FY24, according to US think tank Brookings.
Denne historien er fra January 28, 2025-utgaven av Mint New Delhi.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Mint New Delhi
Mint New Delhi
E-gold firms seek regulatory cover
Digital gold companies may ask the union government to approve their plans for self-regulation if the Securities and Exchange Board of India (Sebi) refuses to regulate the instrument, said a top executive at the India Bullion and Jewellery Association (IBJA), the apex body for all bullion and jewellery associations in India.
3 mins
November 20, 2025
Mint New Delhi
Red Fort blast: Can tech bolster India's security?
The 10 November suicide bombing in the heart of Delhi has raised concerns about public safety in crowded hubs across India. While agencies pursue the perpetrators, police are sharpening their ability to detect security gaps, and fortify defences. Mint looks at the measures.
2 mins
November 20, 2025
Mint New Delhi
How high credit card utilization affects your score: a quick guide
I had a ₹1 lakh credit card bill but repaid ₹40,000; ₹60.000 is due. Will it hurt my credit score? Can I take a personal loan to clear it? Will it affect my score and future loan applications? - Name withheld on request
1 mins
November 20, 2025
Mint New Delhi
Incentives drive each and every participant in all capital markets
Investors must note that everyone is motivated by self-interest whether we know the specifics or not
4 mins
November 20, 2025
Mint New Delhi
India's financial boom: Let's keep progress real
Record funds raised for shareholder exits rather than fresh investment go against the spirit of IPOs. The bigger issue is that the financial world must stay in sync with the real economy
2 mins
November 20, 2025
Mint New Delhi
India Inc's rural engine sputters in Sep quarter
Tepid farm income, sluggish credit growth and an uneven consumption recovery weighed on the momentum of companies linked to rural India in the September quarter, pulling back their pace of growth, even as they stayed ahead of the non-rural pack on some key parameters, a Mint analysis showed.
3 mins
November 20, 2025
Mint New Delhi
Meta's big court win
Social media major Meta has won big relief as a US judge ruled in its favour in an antitrust case filed by the US Federal Trade Commission (FTC) that could have forced it to spin off Instagram and WhatsApp.
1 min
November 20, 2025
Mint New Delhi
xAI in talks to raise $15 billion in fresh equity
Elon Musk's artificial-intelligence startup xAI is in advanced talks to raise $15 billion in fresh equity at a valuation of $230 billion, The Wall Street Journal reported on Tuesday.
1 min
November 20, 2025
Mint New Delhi
AYURVEDIC HOSPITAL CARE: WHY INSURERS PUSH BACK—AND HOW TO WIN CLAIMS
Over the past few years, a friend has undergone Ayurvedic treatment for fluctuating blood pressure at a Kerala hospital. The insurer had routinely covered a week of hospitalization, but this time rejected the claim, arguing the annual treatment appeared more like rest than medical necessity. Ayurvedic claims are becoming harder to get approved.
3 mins
November 20, 2025
Mint New Delhi
Fabindia-Biome row now in arbitration
The founders of personal care company Biome Life Sciences India Pvt. Ltd on Wednesday told the Delhi high court that they were withdrawing their petition against parent Fabindia Ltd over share valuations.
2 mins
November 20, 2025
Listen
Translate
Change font size

